How bankrupt Pa. drug firm Endo could earn $265 million on an ‘exceptionally powerful opioid’ it removed twice from market

  • 📰 PhillyDailyNews
  • ⏱ Reading Time:
  • 23 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 12%
  • Publisher: 67%

Россия Новости Новости

Россия Последние новости,Россия Последние новости

Daily News | How bankrupt Pa. drug firm Endo could earn $265 million on an ‘exceptionally powerful opioid’ it removed twice from market

in September. Pennsylvania Attorney General Josh Shapiro was one of the seven whose filing called the top executive pre-bankruptcy bonuses “excessive.”

In 1970, 309 “addict-patients” at the city-run Philadelphia General Hospital spoke about their drug abuse. One-in-five said they abused Numorphan at least once, according to the 1972 published report on the findings. In 1982, Endo’s then-owner DuPont withdrew Numorphan tablets from the market for “commercial reasons” and amid “anecdotal reports of abuse by injection,” according to a FDA review of oxymorphone’s regulatory history.

 

Спасибо за ваш комментарий. Ваш комментарий будет опубликован после проверки
Мы обобщили эту новость, чтобы вы могли ее быстро прочитать.Если новость вам интересна, вы можете прочитать полный текст здесь Прочитайте больше:

 /  🏆 89. in RU

Россия Последние новости, Россия Последние новости